Lifeboat Foundation

The interdisciplinary nexus of biology and engineering, known as synthetic biology, is growing at a rapid pace, opening new vistas that could scarcely be imagined a short time ago.

DARPA’s Safe Genes program plans to invest $65 million in seven teams that will collect data and develop gene editing tools to support bio-innovation and combat bio-threats such as invasive species.

Gene editing aims to make precise changes to the target DNA whilst avoiding altering other parts of the DNA. The objective of this is to remove undesirable genetic traits and introduce desirable changes in both plants and animals. For example, it could be used to make crops more drought resistant, prevent or cure inherited genetic disorders or even treat age-related diseases.

As some of you may recall, back in May a study was published which claimed that the groundbreaking gene editing technique CRISPR caused thousands of off target and potentially dangerous mutations[1]. The authors of the paper called for regulators to investigate the safety of the technique, a move that could potentially set back research years if not decades.

This publication has been widely blasted by the research community due to serious questions about the study design being raised. One of the problems with this original paper was that it involved only three mice, this is an extremely poor number to make the kind of conclusions the paper did. There have been calls for the paper to be withdrawn and critical responses to the study.

DARPA created the Safe Genes program to gain a fundamental understanding of how gene editing technologies function; devise means to safely, responsibly, and predictably harness them for beneficial ends; and address potential health and security concerns related to their accidental or intentional misuse. Today, DARPA announced awards to seven teams that will pursue that mission, led by: The Broad Institute of MIT and Harvard; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology; North Carolina State University; University of California, Berkeley; and University of California, Riverside. DARPA plans to invest $65 million in Safe Genes over the next four years as these teams work to collect empirical data and develop a suite of versatile tools that can be applied independently or in combination to support bio-innovation and combat bio-threats.

Gene editing technologies have captured increasing attention from healthcare professionals, policymakers, and community leaders in recent years for their potential to selectively disable cancerous cells in the body, control populations of disease-spreading mosquitos, and defend native flora and fauna against invasive species, among other uses. The potential national security applications and implications of these technologies are equally profound, including protection of troops against infectious disease, mitigation of threats posed by irresponsible or nefarious use of biological technologies, and enhanced development of new resources derived from synthetic biology, such as novel chemicals, materials, and coatings with useful, unique properties.

Achieving such ambitious goals, however, will require more complete knowledge about how gene editors, and derivative technologies including gene drives, function at various physical and temporal scales under different environmental conditions, across multiple generations of an organism. In parallel, demonstrating the ability to precisely control gene edits, turning them on and off under certain conditions or even reversing their effects entirely, will be paramount to translation of these tools to practical applications. By establishing empirical foundations and removing lingering unknowns through laboratory-based demonstrations, the Safe Genes teams will work to substantially minimize the risks inherent in such powerful tools.

For decades, biologists have read and edited DNA, the code of life. Revolutionary developments are giving scientists the power to write it. Instead of tinkering with existing life forms, synthetic biologists may be on the verge of writing the DNA of a living organism from scratch. In the next decade, according to some, we may even see the first synthetic human genome. Join a distinguished group of synthetic biologists, geneticists and bioengineers who are edging closer to breathing life into matter.

Watch the full program here: https://youtu.be/rU_pfCtSWF4

Continue reading “Synthetic Biology and the Future of Creation” »

Optimizing human output is the next wave in tech growth, according to Michael Brandt, co-founder of Nootrobox.

Rudrapur, Uttrakhand, India — July 02, 2017

Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational regenerative therapeutic applications, has announced that it is continuing to advance their novel, multi-modality clinical intervention in the state of brain death in humans.

“We have proactively continued to advance our multi-modality protocol, as an extended treatment before extubation, in an attempt to reverse the state of brain death” said Mr.Pranjal Agrawal, CEO Revita Life Sciences. “This treatment approach has yielded some very encouraging initial outcome signs, ranging from minor observations on blood pressure changes with response to painful stimuli, to eye opening and finger movements, with corresponding transient to permanent reversal changes in EEG patterns.”

Continue reading “Revita Life Sciences Continues to Advance Multi-Modality Protocol in Attempt to Revive Brain Dead Subjects” »

Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.

“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”

Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.

Continue reading “Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement” »

A team of researchers believe they could bring back the woolly mammoth from extinction within the next two years.